Biotech Rallied Strongly On Exclusive Licensing Agreement

Biotech Rallied Strongly On Exclusive Licensing Agreement

By: Tomas Ronolski - News

Tuesday, February 27, 2024

A California-based biotech company is turning heads during Tuesday’s session after the company announced it entered into an exclusive licensing agreement for newly engineered double-stranded DNA ligase with Roche, according to a press release. 

Shares of Codexis Inc. (Nasdaq: CDXS) rallied strongly on the news, with shares of the small cap climbing up to $4.43/share (+38.44%) at the early session high. Be sure to add this one to the watchlist.

Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment.

Copyright © 2024 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Canadian Inflation Moves Up as Expected But Easing Underlying Pressures Boost Hopes of June Rate Cut
Micro Cap Has Strong Reaction To Share Repurchase Program
Shares Up as Firm Launches First Short Spot Bitcoin ETP in the Nordics
Most Popular
FREE Newsletter Favorites

Back to Top